Salute e Benessere
Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687
AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous administration. Highly translational preclinical studies have shown that AT-7687 attenuates weight gain and enhances GLP-1-mediated weight loss while improving lipid profiles, particularly LDL, independent of weight change. Importantly, these benefits are not associated with gastrointestinal side effects. The upcoming Phase I trial will assess safety, tolerability, and pharmacokinetics of AT-7687 alone and in combination with semaglutide in healthy lean and healthy obese subjects.
The development of AT-7687 builds on the groundbreaking discovery of a novel human metabolite by world-renowned Professor Jens Holst , the discoverer of GLP-1, and his colleagues. In addition to promising preclinical data, the therapeutic potential of AT-7687 is further supported by robust human genetic validation, demonstrating that reducing GIP receptor activity is associated with leanness.
Antag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs. For more information, please visit https://antagtherapeutics.com .
View original content: https://www.prnewswire.co.uk/news-releases/antag-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-lead-molecule-at-7687-302270536.html